Heart failure hospitalization reduction on semaglutide — looking for input

PharmHunterJen said:

marcus_mpls said: ...cardiovascular risk is just another fad...

This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.

One thing that is still open after Dr.LipidDallas’s answer:

What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?

BiostatsBrad said:

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

That is the short version; the long version is somebody else's post.

BiostatsBrad said:

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…

6 month update on cardiovascular risk: down 51 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Moderator note: a couple of off-topic posts removed.